Table 1 Baseline characteristics of patients with CRE infections who received ceftazidime/avibactam compared with comparative group (received different CRE specific antibiotics)
Characteristic | Ceftazidime/Avibactam group n = 10 (%) | Comparative group n = 28 (%) | P value |
|---|---|---|---|
Male | 8 (80) | 16 (57.1) | 0.27 |
Age, median (IQR), y | 59.5 (26–67) | 61.5 (50–72) | 0.71 |
CCI, median (IQR) | 5.5 (2–8.5) | 5 (4–7.75) | 0.86 |
Baseline comorbidities | |||
Diabetes mellitus | 4 (40) | 15 (53.6) | 0.71 |
Hypertension | 5 (50) | 18 (64.3) | 0.47 |
CVD | 4 (40) | 9 (32.1) | 0.71 |
Renal disease | 3 (30) | 12 (42.8) | 0.71 |
Malignancy | 5 (50) | 7 (25) | 0.24 |
Transplant | 5 (50) | 5 (17.9) | 0.09 |
HIV | 0 | 1 (3.6) | > 0.99 |
Time from admission to first isolate of CRE culture (days), median (IQR), days | 22.5 (4.75–50.75) | 17 (5.25–29.25) | 0.71 |
CRE Bacteremia | 7 (70) | 15 (53.6) | 0.47 |
Type of infection | |||
CLABSI | 1 (10) | 4 (14.3) | > 0.99 |
HAP | 5 (50) | 14 (50) | > 0.99 |
cUTI | 3 (30) | 8 (28.6) | > 0.99 |
cIAI | 3 (30) | 5 (17.8) | 0.41 |
SSTI | 2 (20) | 3 (10.7) | 0.59 |
Microbiology | |||
Klebsiella pneumoniae | 7 (70) | 23 (82.1) | 0.41 |
Escherichia coli | 3 (30) | 5 (17.9) | |
Time from first CRE culture to starting CRE specific therapy, median (IQR), days | 3.5 (1–8.75) | 0 (0–1) | 0.05 |